Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Granella

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|September 4, 2024
Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Journal of Neurology|May 28, 2024
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Brain : a Journal of Neurology|September 16, 2020
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, Mattia Fonderico, Emilio Portaccio, et al.
Neurology|December 21, 2022
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisGiacomo Boffa, Alessio Signori, Luca Massacesi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|September 4, 2024
Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Journal of Neurology|May 28, 2024
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Brain : a Journal of Neurology|September 16, 2020
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, Mattia Fonderico, Emilio Portaccio, et al.
Neurology|December 21, 2022
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisGiacomo Boffa, Alessio Signori, Luca Massacesi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Pageof 12